Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology.
+ 1 more risk
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Biostage's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: H3AA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: H3AA exceeded the German Biotechs industry which returned -5.1% over the past year.
Return vs Market: H3AA exceeded the German Market which returned -17.5% over the past year.
Price Volatility Vs. Market
How volatile is Biostage's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Biostage undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate H3AA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate H3AA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: H3AA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: H3AA is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate H3AA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: H3AA is overvalued based on its PB Ratio (27.3x) compared to the DE Biotechs industry average (3.6x).
How is Biostage forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biostage has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Biostage's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Biostage competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Biostage performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: H3AA is currently unprofitable.
Growing Profit Margin: H3AA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: H3AA is unprofitable, but has reduced losses over the past 5 years at a rate of 7.3% per year.
Accelerating Growth: Unable to compare H3AA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: H3AA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: H3AA has a negative Return on Equity (-766.37%), as it is currently unprofitable.
How is Biostage's financial position?
Financial Position Analysis
Short Term Liabilities: H3AA's short term assets ($1.5M) exceed its short term liabilities ($918.0K).
Long Term Liabilities: H3AA's short term assets ($1.5M) exceed its long term liabilities ($23.0K).
Debt to Equity History and Analysis
Debt Level: H3AA is debt free.
Reducing Debt: H3AA had no debt 5 years ago.
Inventory Level: H3AA has a high level of physical assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if H3AA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: H3AA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if H3AA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Biostage's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate H3AA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate H3AA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if H3AA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if H3AA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of H3AA's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yu Hong (46yo)
Mr. Yu Hong has been Principal Executive Officer at Biostage, Inc. since March 22, 2020. Mr. Yu has been President of Biostage, Inc. since May 29, 2018. Mr. Yu has a depth of experience in cross-border bus ...
|Co-Chairman of Scientific Advisory Board||4.33yrs||no data||no data|
|Co-Chairman of Scientific Advisory Board||no data||no data||no data|
|Independent Director||1.33yrs||US$28.01k||0.29% $90.2k|
|Independent Director||2yrs||US$40.18k||no data|
|Member of Scientific Advisory Board||2yrs||no data||no data|
|Chairman of the Board||2yrs||US$42.92k||0.42% $129.9k|
|Member of Scientific Advisory Board||2.17yrs||no data||no data|
|Independent Director||1.83yrs||US$37.16k||no data|
|Independent Director||1.33yrs||US$28.01k||no data|
Experienced Board: H3AA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 79.8%.
Biostage, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Biostage, Inc.
- Ticker: H3AA
- Exchange: BST
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$34.082m
- Listing Market Cap: US$30.739m
- Shares outstanding: 8.52m
- Website: https://biostage.com
Number of Employees
- Biostage, Inc.
- 84 October Hill Road
- Suite 11
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BSTG||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Apr 2013|
|H3AA||BST (Boerse-Stuttgart)||Yes||Common Shares||DE||EUR||Apr 2013|
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company’s Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient’s own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/30 00:07|
|End of Day Share Price||2020/03/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.